Maria Oliva-Hemker, CCC 2021: Treatment Updates: Where Do Immunomodulators Fit in Current Approaches to Therapy? (Part 1)
It was a pleasure to talk to Maria Oliva-Hemker (Johns Hopkins University School of Medicine, Baltimore, MD, US) around her presentation on ‘Treatment Updates: Where Do Immunomodulators Fit in Current Approaches to Therapy?’ which was presented at the virtual 2021 Crohn’s & Colitis Congress.
- What has clinical data taught us about the role of immunomodulator monotherapy for induction and maintenance of remission in paediatric IBD therapy? (0:15)
- At what stage would you advise a step up to anti-TNF therapy? (4:22)
- When should we use immunotherapy in combination with anti-TNFs agents? (5:31)
Disclosures: Maria Oliva-Hemker has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Digestive Disorders
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023
Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!